Warning letter · FDA Warning Letters

Cannafyl: FDA Warning Letter 611957 (Mar 1, 2021)

Agency action: Mar 1, 2021Record ID: fda_warning_-5d30d68cd24c0f0d
View official source ↗

What happened

Original notice title

Cannafyl MARCS-CMS 611957, March 01, 2021

From the archived source record

The claims on your website and social media websites establish that all strengths and varieties of your “Balance CBD Drops,” 2 “Relief CBD Drops,” 3 “Relax CBD Drops,” 4 and “Relief CBD Salve” 5 (hereinafter all referred to as “your CBD-containing products for humans”) are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your CBD-containing products for humans are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). In addition, your “Pet CBD Drops” 6 is an unapproved new animal drug that is unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and is adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue. 10 Unapproved New Drugs Based on our review of your website and social media websites, your CBD-containing products for humans are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body. Misbranded Drugs Your CBD-containing products for humans are also misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
No closeout listed in FDA table
Source checked
Jul 16, 2026
Record revision
dd144160a936

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Relief CBD Salve; Balance CBD Drops; Relief CBD Drops; Relax CBD Drops; Pet CBD Drops; and “Relax CBD Drops” as dietary supplements; webpage for “Pet CBD Drops” at https://cannafyl
Company
Cannafyl
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.